STRATEGIC REPORT

Strong patient growth across all the operating platforms

Continued investments in patient experience and clinical qualities initiatives

Successful completion of Mediclinic and Al Noor Combination and acquisition of 29.9% stake in Spire Healthcare Group

Solid financial performance with stable margins and good cash generation

Revenue growth of 7% with stable margins at 20.3% driving strong underlying earnings growth

Underlying basic earnings per share increased by 3% to 36.7 pence

Proposed final dividend per ordinary share of 5.24 pence

* IFRS measure
** Non-IFRS measure

See the reconciliations between the statutory and underlying (non-GAAP) measures.